Literature DB >> 6284899

Natural history of parainfluenza virus infection in childhood.

R Welliver, D T Wong, T S Choi, P L Ogra.   

Abstract

In order to determine the natural history of parainfluenza virus infection in early life, we followed prospectively 130 infants and children from birth or a few months of age for evidence of infection with PV. Using rapid diagnostic techniques, standard tissue culture infectivity, and serologic techniques we were able to document primary PV infection in 92% of these infants, and repeated infection with heterotypic or homotypic PV strains in 49% by 30 months of age. Increasing patient age had no significant effect in reducing the incidence of lower respiratory tract illness as a result of PV infection. Infection with one PV serotype provided no protection against LRTI at the time of subsequent infection with a heterotypic PV strain. In contrast, primary PV infection provided a brief period of immunity to LRTI upon homotypic reinfection. Secretory IgA responses to PV were determined by immunofluorescent techniques. Antibody response to PV strains causing primary infection and heterotypic repeated infection were transient and of low magnitude. Homotypic reinfection resulted in significantly enhanced production of secretory antibody to PV. At least in early life, repeated exposures to PV appear to be essential for maintaining immunity to severe forms of illness caused by PV infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284899     DOI: 10.1016/s0022-3476(82)80113-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Characterization of human parainfluenza virus type 3 persistent infection in cell culture.

Authors:  A Moscona; M S Galinski
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

2.  Intracellular synthesis of human parainfluenza type 3 virus-specified polypeptides.

Authors:  S L Wechsler; D M Lambert; M S Galinski; M W Pons
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

3.  Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997.

Authors:  H Laurichesse; D Dedman; J M Watson; M C Zambon
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

4.  Inter- and intra-patient sequence diversity among parainfluenza virus-type 1 nucleoprotein genes.

Authors:  V P Dave; S V Hetherington; A Portner; R J Leggiadro; J L Hurwitz
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

5.  The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3.

Authors:  S Sieg; C King; Y Huang; D Kaplan
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Detection of respiratory syncytial virus A and B and parainfluenzavirus 3 sequences in respiratory tracts of infants by a single PCR with primers targeted to the L-polymerase gene and differential hybridization.

Authors:  G Eugene-Ruellan; F Freymuth; C Bahloul; H Badrane; A Vabret; N Tordo
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

7.  Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay.

Authors:  J Fan; K J Henrickson
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

8.  Human parainfluenza virus type 3 up-regulates major histocompatibility complex class I and II expression on respiratory epithelial cells: involvement of a STAT1- and CIITA-independent pathway.

Authors:  J Gao; B P De; A K Banerjee
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Infection and immunoregulation of T lymphocytes by parainfluenza virus type 3.

Authors:  S Sieg; C Muro-Cacho; S Robertson; Y Huang; D Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

Review 10.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.